ZEDRA
Fast growing and acquisitive ZEDRA has announced its latest acquisition, this time in Poland. ZEDRA will acquire Awans Corporate Services, one of Poland’s oldest corporate services specialists, which has been offering accounting and administration services to local companies, corporations and individuals, for over 20 years. This new acquisition follows on from deals in Singapore, the Isle of Man, Switzerland, Nordic markets signed and announced in 2019.
With a focus on local entrepreneurs and medium sized companies, Awans Corporate Services is a leading provider of accounting, human resources and payroll management services to companies based in Poland. The company also offers traditional corporate services, including incorporation services, cash management and business advisory.
Unveiling the acquisition, Ivo Hemelraad, CEO of ZEDRA said: “This latest deal will mark our first move into the vibrant and fast growing Central European markets. With a population of nearly 38 million, together with a strong tradition for business startups and growth, we see Poland as a dynamic and important new market for ZEDRA. I am looking forward to welcoming the staff and clients of Awans Corporate Services to ZEDRA.” Piotr Augustyniak, founder of Awans Corporate Services, who is to become ZEDRA’s Head of Central Europe at completion, stated: “As one of Poland’s oldest providers of high quality corporate services solutions, we will be bringing a unique depth of knowledge and expertise to ZEDRA.”
Bartek Bielski, Managing Director of Awans Corporate Services, which will be renamed ZEDRA Poland following completion, added: “Our nearly 20 staff have always focussed on providing best in class solutions to our clients. The opportunity to become part of ZEDRA, with its proactive and positive ‘do more, achieve more’ approach, and getting access to its international network of professionals is one which we found compelling and certainly in the best interest of our staff and clients”.
The deal will bring ZEDRA’s existing headcount to over 550 industry experts and expand its global footprint to 14 countries, spanning Asia, Oceania, the Americas and Europe.
Editor notes
About ZEDRA
https://www.zedra.com/boilerplate/
About Awans Corporate Services
Awans Corporate Services is one of the companies with the longest history on the Polish market providing financial services and business support in the area of accounting and administration services.
The team consists of experienced specialists in the field of corporate services. Awans Corporate Services provides reliable and comprehensive accounting, human resources and payroll management services, as well as cost-effective solutions in the design and administration of companies and business consulting for small and medium-sized companies, corporations and individuals, in particular in the liberal professions (freelancers), ensuring ongoing compliance with Polish law and tax regulations.
Awans Corporate Services gained trust of many foreign companies, supporting them in developing business projects in Poland.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005134/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom